DOMPERIDONE 10 mg ORO-DISPERSIBLE TABLET

DOMPERIDONE 10 mg ORO-DISPERSIBLE TABLET
Product Description

UNIQUE SELLING POINT:

  • Firstline treatment of nausea and vomiting acting with lower potential to induce dystonic, extrapyramidal symptoms or galactorrhoea.
  • Orodispersible tablet formulation facilitating water-free intake by oral route in patients suffering from nausea and vomiting or who have difficulties in swallowing.
  • Selective D2/D3 dopamine antagonist.
  • Combine prokinetic and anti-emetic activities on gastrointestinal tract making it an ideal agent for treating gastroparesis (postprandial fullness, nausea, vomiting and stomach fullness). 
  • Does not cross the blood-brain barrier minimizing CNS adverse events.
  • Domperidone accelerates gastric emptying.
  • Domperidone has better tolerance and has no significant drug interaction.

Athena

  • IN
  • 2015
    On CPhI since
Specifications
  • Details
    Strenght:10mg
  • Selling Points
    International Approvals/Standards
  • Supplied from
    India
  • Measured In
    mg

Athena

  • IN
  • 2015
    On CPhI since

More Products from Athena

  • DONEPEZIL 5/10 mg ORO DISPERSIBLE TABLET

    Product DONEPEZIL 5/10 mg ORO DISPERSIBLE TABLET

    UNIQUE SELLING POINT:
    • Donepezil Oro-Dispersible Tablet is pleasant and convenient as a tablet that melts in the mouth and can be administered anytime anywhere with or without water.
    • Unique technology of Athena is an ideal choice for patients with Alzheimer’s disease(AD).
    • Significant improvement in cognitive and global functions, activity of daily living and in patients suffering from light, moderate or severe Alzheimer’s disease after 12-24 weeks of treatment vs. placebo.
    • Clinical improvements in non-cognitive behaviours and in caregiver stress.
    • Reduction of the two core symptoms of dementia, i.e. agitation and delusions.
    • Commonly used in Lewy Body dementia and reduce visual hallucinations.
    • Lesser behaviour deterioration vs. Galantamine.
    • Superior Global Responder Rate vs. Galantamine. 
    • Lower risk of treatment withdrawals for any reason or because of an adverse event for Donepezil vs. Rivastigmine or Galantamine.
  • FENOFIBRATE 67/200/267 MG CAPSULE

    Product FENOFIBRATE 67/200/267 MG CAPSULE

    UNIQUE SELLING POINT:

    • Micronized formulation results improving patient’s compliance, daily dose reduction whilst ensuring an optimal drug efficacy.
    • Fenofibrate is a third generation fibric acid practically insoluble in water, making it challenging to consistently achieve therapeutic levels. 
    • Micronization technology dramatically improves the dissolution rate-limited gastrointestinal absorption.
    • Fenofibrate activates peroxisome proliferator activated receptor type alpha (PPARa) that increases the lipolysis and elimination of atherogenic particles. 


  • IBUPROFEN 200/400mg ORO- DISPERSIBLE TABLET

    Product IBUPROFEN 200/400mg ORO- DISPERSIBLE TABLET

    UNIQUE SELLING POINT: 
    • Athena’s ODT technology is a perfect fit for bedridden patients or patients with difficulties in swallowing or chewing conventional solid dosage forms, without need for water at the time of administration.
    • Rated as the safest non-steroidal anti-inflammatory Drug by spontaneous adverse drug reaction reporting in the UK.
    • Prominent analgesic & antipyretic activities particularly useful in the management of pain related to dysmenorrhea, headache, postoperative dental pain and rheumatoid arthritis.
    • Ibuprofen is among the most prescribed pain-relieving drugs.
  • LEVOCETIRIZINE 5mg Oro-DISPERSIBLE TABLET

    Product LEVOCETIRIZINE 5mg Oro-DISPERSIBLE TABLET

    UNIQUE SELLING POINT
    • Levocetirizine Oro‐Dispersible Tablet is pleasant and convenient as a tablet that melts inmouth and can be administered anytime anywhere with or without water.
    • Levocetirizine is considered as a first line treatment for allergic conditions such as hayfever; year round allergies, and chronic nettle rash.
    • Levocetirizine is free from sedative effects.
    • Levocetirizine efficacy superior to loratadine, desloratadine and fexofenadine.
    • 43% saving on the social cost of persistent allergic rhinitis9.
    • Minimal impairment of memory and psychomotor functioning nor mood changes after acute and sub chronic administration of levocetirizine.
  • MELOXICAM 7.5/15 mg ORO DISPERSIBLE TABLET

    Product MELOXICAM 7.5/15 mg ORO DISPERSIBLE TABLET

    UNIQUE SELLING POINT
    • Oro-dispersible tablet facilitates oral intake and improves patients’ compliance
    • Once-a-day administration.
    • Meloxicam appears to have better gastrointestinal tolerance than non-selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) thanks to its preferential inhibition of COX-2 vs. COX-1. The Oro-dispersible tablets enhance patient compliance, administration without water and accuracy of dosage.
    • Meloxicam, compared to diclofenac1 piroxicam2 or naproxen3, 4, caused less gastrointestinal related adverse events (respectively 13% vs. 19%; p=0.001; 10.3% vs. 15.4%; p=0.001 and 0.36 events per patient vs. 0.52; p=0.002).
    • Meloxicam is equivalent to Diclofenac SR in relieving acute pain associated with osteoarthritis and has much better tolerance.
  • ONDANSETRON 4/8 MG ORO DISPERSIBLE TABLET

    Product ONDANSETRON 4/8 MG ORO DISPERSIBLE TABLET

    UNIQUE SELLING POINT:
    • Thanks to Athena’s oro-dispersible technology, not requiring water, a rapid drug intervention therapy with ondansetron can be achieved (melting < 30 sec.), in patients suffering from chemotherapy-induced nausea and vomiting who are unable/reluctant to swallow.
    • Ondansetron, a serotonin 5-HT3 receptor antagonist is effective in the control of nausea and vomiting in patients treated by highly emetogenic chemotherapy and after radiotherapy. 
    • Furthermore, ondansetron shows clinical benefits in the management of patients receiving highly emetogenic chemotherapy who have poorly responded to conventional antiemetics, or who suffer from intolerable side effects. 
    • Ondansetron is also indicated for the prevention and treatment of postoperative nausea and vomiting. 
    • In pediatrics (4-18y) ondansetron is effective and well tolerated in the treatment of post-chemotherapy induced nausea and vomiting. 
    • Ondansetron is on the WHO List of Essential Medicines.
  • RACECADOTRIL SACHET 10/30 MG

    Product RACECADOTRIL SACHET 10/30 MG

    UNIQUE SELLING POINT:

    • Racecadotril is a guideline-recommended treatment to alleviate symptoms of acute diarrhoea. 
    • Safety profile is similar to that of placebo. 
    • Racecadotril inhibits the degradation of enkephalins, which in turn have potent anti-secretory activity but only little effect on motility in the gut in contrast to loperamide (IMODIUM®). 
    • Resolution of symptoms with racecadotril when compared to loperamide is associated with less rebound constipation and less abdominal discomfort.
    • Reduction of water and electrolytes losses in children suffering from acute diarrhoea.
    • Racecadotril is indicated for the complementary symptomatic treatment of acute diarrhoea in infants aged over3 months.
    • Fewer side effects in comparison to Loperamide2, Imodium®.
    • Can be used in Invasive Diarrhoea 
  • TRAMADOL 37.5 MG + PARACETAMOL 325 MG ORO DISPERSIBLE TABLET

    Product TRAMADOL 37.5 MG + PARACETAMOL 325 MG ORO DISPERSIBLE TABLET

    UNIQUE SELLING POINT:
    • Oro-dispersible technology facilitates oral intake and improves patients’ compliance.
    • Fixed-combination, offering a convenient method of intake maximizing analgesic efficacy whilst reducing daily tramadol and paracetamol doses, hence minimizing tramadol’s potential for dependence and misuse and paracetamol hepatotoxicity.
    • Fixed-combination of two well-known and established analgesics, devoid of the gastrointestinal, cardiovascular and renal adverse events associated with Non-Steroidal Anti-inflammatory Drugs (NSAIDs) responsible for 3.500-16.500 death per year in the USA.
    • Fixed-dose combination treatment reduces tramadol consumption by 24% vs. Tramadol monotherapy. Fixed combination extensively evaluated than other combination products. 
    • Only fixed-combination where both the dual mechanism of action and synergy between the two compounds have been demonstrated in both preclinical studies and in humans.
  • TRAMADOL 37.5 MG + PARACETAMOL 325 MG TABLET

    Product TRAMADOL 37.5 MG + PARACETAMOL 325 MG TABLET

    UNIQUE SELLING POINT:
    • Fixed-combination maximizing analgesic efficacy whilst reducing daily tramadol and paracetamol doses, hence minimizing tramadol’s potential for dependence and misuse and paracetamol hepatotoxicity.
    • Fixed-combination of two well-known and established analgesics, devoid of the gastrointestinal, cardiovascular and renal adverse events associated with Non-Steroidal Anti-inflammatory Drugs (NSAIDs) responsible for 3.500-16.500 death per year in the USA.
    • Fixed-dose combination treatment reduces tramadol consumption by 24% vs. Tramadol monotherapy.  
    • Fixed combination extensively evaluated than other combination products. Only fixed-combination where both the dual mechanism of action and synergy between the two compounds have been demonstrated in both preclinical studies and in humans.
  • ZOLPIDEM 5/10 MG ORO DISPERSIBLE TABLET

    Product ZOLPIDEM 5/10 MG ORO DISPERSIBLE TABLET

    UNIQUE SELLING POINT:
    • ODT technology particularly suitable in insomnia patients who have difficulties swallowing tablets, or those who may not, or do not, always have access to water at bedtime.
    • Selective binding hence very strong hypnotic properties.
    • Zolpidem is particularly suitable for insomniac patient suffering with difficulties with sleep initiation.
  • PREDNISOLONE SODIUM PHOSPHATE 5/10 MG SOLUBLE TABLETS

    Product PREDNISOLONE SODIUM PHOSPHATE 5/10 MG SOLUBLE TABLETS

    UNIQUE SELLING POINT
    • Massive improvement in patient’s treatment adherence (especially in children) over liquid preparation based on solid tablet forms which requires hazardous manipulations (crushing, scoring, or adding excipients) that may affect stability, cause inaccurate dosing and be hazardous for the ersatz compounder.
    • Prednisolone is highly effective and significantly more effective that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in rheumatoid arthritis and may be used intermittently.
    • Prednisolone is the active metabolite of prednisone and prednisone’s efficacy is related to the patient’s hepatic function capacity to convert prednisone to prednisolone.
    • Prednisolone is on the World Health Organization’s List of Essential Medicine.
    • Sodium phosphate prednisolone should be preferred over prednisolone base as it is less bitter in order to improve children’s acceptance.
  • METFORMIN 750 MG SUSTAINED RELEASE TABLET

    Product METFORMIN 750 MG SUSTAINED RELEASE TABLET

    UNIQUE SELLING POINT 
    • Sustained-release formulation for type 2 diabetic patients, improving Gastrointestinal tolerability whilst allowing for a once‑daily dosing.
    • Outstanding ability to decrease plasma glucose levels in type 2 diabetic patients.
    • First-line treatment of type 2 diabetes.
    • Treatment of choice in pregnant women with type 2 diabetes.
    • Superior efficacy than conventional agents (chlorpropamide, glibenclamide, insulin) in type 2 diabetic patients for any diabetes-related endpoint, diabetic-related death and for all-cause mortality. 
    • Associated with less weight gain and fewer hypoglycaemic attacks
    • Better tolerability- reduces GI side effects like nausea, abdominal pain, diarrhoea.

Recommended products